Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using latanoprost for hair loss treatment. Participants also mention Minoxidil, finasteride, and RU58841 as other treatments.

Minoxidil alone gave one user only short fuzzy hair after a year. They're now trying a 0.5 microneedling roller and seeking opinions on its effectiveness after using minoxidil.

The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.

User experienced shedding and bald spots after 1 month of using Redensyl. Considering trying CosmeRNA as alternative treatment.

Use rosemary oil 2-3 times a week, ideally after derma rolling, for optimal results. This routine can complement other treatments like Minoxidil, finasteride, or RU58841.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

Microneedling for hair loss, with concerns about cost and conflicting information on protocols. The user is unsure about purchasing and reusing microneedling stampers.

A 21-year-old is using Dualgen-5R (minoxidil and tretinoin) and weekly dermarolling to address hair loss, noticing some progress after three months. They plan to add an anti-androgen like RU58841 or Kx826 for better long-term results.

OP is using oral 1mg finasteride, topical minoxidil, and microneedling twice a month at .75mm to regrow hair. They shared progress pictures over two months, noting they were bald for years before starting treatment.

The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.

Hair loss treatments, specifically the use of Minoxidil, Finasteride, and RU58841 to promote hair growth in areas such as the crown and temples. The user has shared their progress since August 2022 after using Manual's all-in-one capsule treatment plan.

The conversation discusses the effectiveness of topical Rapamycin for hair regrowth and color restoration. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hair growth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.

A 31-year-old used topical minoxidil and finasteride with weekly microneedling for 3.5 weeks, seeing improvements in the crown and frontal areas. They are happy with the results and curious about the 3-month mark.

The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

Oral minoxidil combined with microneedling shows benefits for hair loss. One user reported using a 0.5 mm depth every other day with positive results.

A user shared their positive experience and results 10 months after a hair transplant at Mercure Istanbul Clinics, using 3000 grafts. They expressed satisfaction with both the outcome and the clinic's service.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The post and conversation are about using bimatoprost for hair regrowth, with the user seeking a higher concentration to enhance results. The user also discusses difficulties in sourcing the powder for personal use.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.